Internal Medicine, Gastroenterology · Canton, OH
NPI
1497750822
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4360 Fulton Dr NW Ste B
Canton, OH, 44718
Phone (330) 305-2020
Groups this clinician bills Medicare through
Medicare paid, 2024
$107K
825 services
Medicare patients, 2024
610
Average age 73
Drug cost, 2024
$1.3M
6,188 prescriptions
Company payments, 2025
$16.84
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nabil Fahmy was code 43239 (upper gi endoscopy), 224 times for 218 patients. In total Nabil Fahmy billed 825 services in 38 codes, and Medicare paid $107K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 43239 Upper GI Endoscopy | Facility | 224 | 218 | $94.31 | $21K |
| 45385 Colonoscopy - Lesion Removal | Facility | 173 | 173 | $199.81 | $35K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 101 | 101 | $169.24 | $17K |
| 99222 Hospital E&M - Initial | Facility | 36 | 34 | $98.34 | $3,540 |
| 45380 Lower GI Endoscopy - Other | Facility | 28 | 28 | $126.11 | $3,531 |
| 99223 Hospital E&M - Initial | Facility | 25 | 25 | $124.61 | $3,115 |
| 45378 Lower GI Endoscopy - Other | Facility | 23 | 23 | $131.78 | $3,031 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 20 | 19 | $148.92 | $2,978 |
| 43249 Upper GI Endoscopy | Facility | 20 | 17 | $107.17 | $2,143 |
| 76981 Ultrasound - Nonspecific | Office | 20 | 20 | $72.11 | $1,442 |
| 43264 Upper GI Endoscopy | Facility | 19 | 16 | $168.96 | $3,210 |
| 99232 Hospital E&M - Subsequent | Facility | 19 | 16 | $58.85 | $1,118 |
| 43235 Upper GI Endoscopy | Facility | 17 | 16 | $83.95 | $1,427 |
| 99233 Hospital E&M - Subsequent | Facility | 15 | 14 | $89.07 | $1,336 |
| 43262 Upper GI Endoscopy | Facility | 12 | 12 | $45.48 | $546 |
By year: 2022 $145K for 1,719 services; 2023 $115K for 933 services; 2024 $107K for 825 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 623 | 294 | $23.78 | $15K |
Medicare prescription drug claims, 2024
In 2024, the drug Nabil Fahmy prescribed most often to Medicare patients was Pantoprazole Sodium, with 1,444 prescriptions and refills. In total Nabil Fahmy wrote 6,188 Medicare prescriptions that cost $1.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 1,444 | 2,934 | 365 | $18K |
| Omeprazole Generic | 1,309 | 2,547 | 320 | $15K |
| Esomeprazole Magnesium Generic | 1,016 | 1,657 | 207 | $25K |
| Famotidine Generic | 266 | 495 | 65 | $2,480 |
| Sucralfate Generic | 238 | 327 | 57 | $16K |
| Lansoprazole Generic | 170 | 335 | 34 | $4,055 |
| Ursodiol Generic | 153 | 292 | 38 | $35K |
| Prednisone Generic | 118 | 194 | 24 | $555 |
| Colestipol Hcl Generic | 114 | 229 | 34 | $11K |
| Balsalazide Disodium Generic | 103 | 177 | 18 | $20K |
| Mesalamine Generic | 95 | 178 | 30 | $50K |
| Azathioprine Generic | 86 | 177 | 21 | $3,565 |
| Dicyclomine Hcl Generic | 81 | 133 | 27 | $1,430 |
| Creon Lipase/Protease/Amylase | 72 | 88 | 16 | $128K |
| Dexlansoprazole Dr Dexlansoprazole | 60 | 94 | 14 | $9,412 |
Brand drugs: 503 claims; generic drugs: 5,685 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nabil Fahmy $16.84 ($16.84 in general payments such as food, travel and fees) from 1 company. The largest payer was Pfizer Inc. with $16.84.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 1 | $16.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.